Osteoporosis in older men

References

• Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos. Int.7(5), 407–413 (1997).
   PubMed Web of Science ®Google Scholar
• Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J. Bone Miner. Res.17(4), 716–724 (2002).
   PubMed Web of Science ®Google Scholar
• Lau E, Ong K, Kurtz S, Schmier J, Edidin A. Mortality following the diagnosis of a vertebral compression fracture in the Medicare population. J. Bone Joint Surg. Am.90(7), 1479–1486 (2008).
   PubMed Web of Science ®Google Scholar
• Piirtola M, Vahlberg T, Löppönen M, Räihä I, Isoaho R, Kivelä SL. Fractures as predictors of excess mortality in the aged – a population-based study with a 12-year follow-up. Eur. J. Epidemiol.23(11), 747–755 (2008).
   PubMed Web of Science ®Google Scholar
• Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet353(9156), 878–882 (1999).
   PubMed Web of Science ®Google Scholar
• Langsetmo L, Hanley DA, Kreiger N et al. Geographic variation of bone mineral density and selected risk factors for prediction of incident fracture among Canadians 50 and older. Bone43(4), 672–678 (2008).
   PubMed Web of Science ®Google Scholar
• Court-Brown CM, Caesar B. Epidemiology of adult fractures: a review. Injury37(8), 691–697 (2006).
   PubMed Web of Science ®Google Scholar
• Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol. Metab. Clin. North. Am.36(2), 399–419 (2007).
   PubMed Web of Science ®Google Scholar
• Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos. Int.4(5), 277–282 (1994).
   PubMed Web of Science ®Google Scholar
• White SC, Atchison KA, Gornbein JA, Nattiv A, Paganini-Hill A, Service SK. Risk factors for fractures in older men and women: The Leisure World Cohort Study. Gend. Med.3(2), 110–123 (2006).
   PubMedGoogle Scholar
• van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone29(6), 517–522 (2001).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Nielson CM, Orwoll E, Bauer DC, Cauley JA; Osteoporotic Fractures in Men Study Group. Epidemiology of rib fractures in older men: Osteoporotic Fractures in Men (MrOS) prospective cohort study. BMJ340, c1069 (2010).
   PubMedGoogle Scholar
• Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr. Rev.29(4), 441–464 (2008).
   PubMed Web of Science ®Google Scholar
• Ahmed LA, Schirmer H, Bjørnerem A et al. The gender- and age-specific 10-year and lifetime absolute fracture risk in Tromsø, Norway. Eur. J. Epidemiol.24(8), 441–448 (2009).
   PubMed Web of Science ®Google Scholar
• Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA301(5), 513–521 (2009).
   PubMed Web of Science ®Google Scholar
• Freitas SS, Barrett-Connor E, Ensrud KE et al. Rate and circumstances of clinical vertebral fractures in older men. Osteoporos. Int.19(5), 615–623 (2008).
   PubMed Web of Science ®Google Scholar
• Chan BK, Marshall LM, Winters KM, Faulkner KA, Schwartz AV, Orwoll ES. Incident fall risk and physical activity and physical performance among older men: the Osteoporotic Fractures in Men Study. Am. J. Epidemiol.165(6), 696–703 (2007).
   PubMed Web of Science ®Google Scholar
• Kenny AM, Smith J, Noteroglu E et al. Osteoporosis risk in frail older adults in assisted living. J. Am. Geriatr. Soc.57(1), 76–81 (2009).
   PubMed Web of Science ®Google Scholar
• Tracy JK, Meyer WA, Grigoryan M et al. Racial differences in the prevalence of vertebral fractures in older men: the Baltimore Men’s Osteoporosis Study. Osteoporos. Int.17(1), 99–104 (2006).
   PubMed Web of Science ®Google Scholar
• Marshall LM, Zmuda JM, Chan BK et al. Race and ethnic variation in proximal femur structure and BMD among older men. J. Bone Miner. Res.23(1), 121–130 (2008).
   PubMed Web of Science ®Google Scholar
• Ferrari S. Human genetics of osteoporosis. Best. Pract. Res. Clin. Endocrinol. Metab.22(5), 723–735 (2008).
   PubMed Web of Science ®Google Scholar
• Khosla S. Update in male osteoporosis. J. Clin. Endocrinol. Metab.95(1), 3–10 (2010).
   PubMed Web of Science ®Google Scholar
• van Meurs JB, Rivadeneira F, Jhamai M et al. Common genetic variation of the low-density lipoprotein receptor-related protein 5 and 6 genes determines fracture risk in elderly white men. J. Bone Miner. Res.21(1), 141–150 (2006).
   PubMed Web of Science ®Google Scholar
• Hong X, Hsu YH, Terwedow H et al. CYP19A1 polymorphisms are associated with bone mineral density in Chinese men. Hum. Genet.121(3–4), 491–500 (2007).
   PubMed Web of Science ®Google Scholar
• Van Pottelbergh I, Goemaere S, Kaufman JM. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J. Clin. Endocrinol. Metab.88(7), 3075–3081 (2003).
   PubMed Web of Science ®Google Scholar
• Lei SF, Jiang H, Deng FY, Deng HW. Searching for genes underlying susceptibility to osteoporotic fracture: current progress and future prospect. Osteoporos. Int.18(9), 1157–1175 (2007).
   PubMed Web of Science ®Google Scholar
• Roshandel D, Holliday K, Pye SR et al. Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men. J. Bone Miner. Res.25(8), 1830–1838 (2010).
   PubMed Web of Science ®Google Scholar
• Dennison EM, Syddall HE, Jameson KA et al. A study of relationships between single nucleotide polymorphisms from the growth hormone-insulin-like growth factor axis and bone mass: the Hertfordshire cohort study. J. Rheumatol.36(7), 1520–1526 (2009).
   PubMed Web of Science ®Google Scholar
• Li WF, Hou SX, Yu B, Li MM, Férec C, Chen JM. Genetics of osteoporosis: accelerating pace in gene identification and validation. Hum. Genet.127(3), 249–285 (2010).
   PubMed Web of Science ®Google Scholar
• Riggs BL, Melton LJ, Robb RA et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J. Bone Miner. Res.23(2), 205–214 (2008).
   PubMed Web of Science ®Google Scholar
• Guggenbuhl P. Osteoporosis in males and females: is there really a difference? Joint Bone Spine76(6), 595–601 (2009).
   PubMed Web of Science ®Google Scholar
• Szulc P, Delmas PD. Bone loss in elderly men: increased endosteal bone loss and stable periosteal apposition. The prospective MINOS study. Osteoporos. Int.18(4), 495–503 (2007).
   PubMed Web of Science ®Google Scholar
• Yates LB, Karasik D, Beck TJ, Cupples LA, Kiel DP. Hip structural geometry in old and old-old age: similarities and differences between men and women. Bone41(4), 722–732 (2007).
   PubMed Web of Science ®Google Scholar
• Orwoll E, Lambert LC, Marshall LM et al. Testosterone and estradiol among older men. J. Clin. Endocrinol. Metab.91(4), 1336–1344 (2006).
   PubMed Web of Science ®Google Scholar
• Meier C, Nguyen TV, Handelsman DJ et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch. Intern. Med.168(1), 47–54 (2008).
   PubMed Web of Science ®Google Scholar
• Fink HA, Ewing SK, Ensrud KE et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J. Clin. Endocrinol. Metab.91(10), 3908–3915 (2006).
   PubMed Web of Science ®Google Scholar
• Vandenput L, Ohlsson C. Sex steroid metabolism in the regulation of bone health in men. J. Steroid Biochem. Mol. Biol.121(3–5), 582–588 (2010).
   PubMed Web of Science ®Google Scholar
• LeBlanc ES, Nielson CM et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J. Clin. Endocrinol. Metab.94(9), 3337–3346 (2009).
   PubMed Web of Science ®Google Scholar
• Mellström D, Vandenput L, Mallmin H et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J. Bone Miner. Res.23(10), 1552–1560 (2008).
   PubMed Web of Science ®Google Scholar
• Frenkel B, Hong A, Baniwal SK et al. Regulation of adult bone turnover by sex steroids. J. Cell. Physiol.224(2), 305–310 (2010).
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Goemaere S. Osteoporosis in men. Best. Pract. Res. Clin. Endocrinol. Metab.22(5), 787–812 (2008).
   PubMed Web of Science ®Google Scholar
• Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT. Ehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am. J. Clin. Nutr.89(5), 1459–1467 (2009).
   PubMed Web of Science ®Google Scholar
• von Mühlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos. Int.19(5), 699–707 (2008).
   PubMed Web of Science ®Google Scholar
• Muller M, van den Beld AW, van der Schouw YT, Grobbee DE, Lamberts SW. Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men. J. Clin. Endocrinol. Metab.91(10), 3988–3991 (2006).
   PubMed Web of Science ®Google Scholar
• Nair KS, Rizza RA, O’Brien P et al. DHEA in elderly women and DHEA or testosterone in elderly men. N. Engl. J. Med.355(16), 1647–1659 (2006).
   PubMed Web of Science ®Google Scholar
• Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys.473(2), 139–146 (2008).
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Kuhne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J. Musculoskelet. Neuronal Interact.4(3), 268–275 (2004).
   PubMedGoogle Scholar
• Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor κB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur. J. Endocrinol.156(5), 555–562 (2007).
   PubMed Web of Science ®Google Scholar
• Kramer I, Halleux C, Keller H et al. Osteocyte Wnt/β-catenin signaling is required for normal bone homeostasis. Mol. Cell. Biol.30(12), 3071–3085 (2010).
   PubMed Web of Science ®Google Scholar
• Liu F, Kohlmeier S, Wang CY. Wnt signaling and skeletal development. Cell. Signal.20(6), 999–1009 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou H, Mak W, Zheng Y, Dunstan CR, Seibel MJ. Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling. J. Biol. Chem.283(4), 1936–1945 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou H, Mak W, Kalak R et al. Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development136(3), 427–436 (2009).
   PubMed Web of Science ®Google Scholar
• Koay MA, Brown MA. Genetic disorders of the LRP5–Wnt signalling pathway affecting the skeleton. Trends. Mol. Med.11(3), 129–137 (2005).
   PubMed Web of Science ®Google Scholar
• Riancho JA, Olmos JM, Pineda B et al. Wnt receptors, bone mass, and fractures: gene-wide association analysis of LRP5 and LRP6 polymorphisms with replication. Eur. J. Endocrinol.164(1), 123–131 (2011).
   PubMed Web of Science ®Google Scholar
• Grundberg E, Lau EM, Lorentzon M et al. Large-scale association study between two coding LRP5 gene polymorphisms and bone phenotypes and fractures in men. Osteoporos. Int.19(6), 829–837 (2008).
   PubMed Web of Science ®Google Scholar
• Papaioannou A, Kennedy CC, Cranney A et al. Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporos. Int.20(4), 507–518 (2009).
   PubMed Web of Science ®Google Scholar
• Michaëlsson K, Olofsson H, Jensevik K et al. Leisure physical activity and the risk of fracture in men. PLoS Med.4(6), e199 (2007).
   PubMed Web of Science ®Google Scholar
• Tucker KL, Jugdaohsingh R, Powell JJ et al. Effects of beer, wine, and liquor intakes on bone mineral density in older men and women. Am. J. Clin. Nutr.89(4), 1188–1196 (2009).
   PubMed Web of Science ®Google Scholar
• Orwoll E, Nielson CM, Marshall LM et al. Vitamin D deficiency in older men. J. Clin. Endocrinol. Metab.94(4), 1214–1222 (2009).
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B, Mithal A, Bonjour JP et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int.21(7), 1151–1154 (2010).
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Taylor BC, Paudel ML et al. Serum 25-hydroxyvitamin D levels and rate of hip bone loss in older men. J. Clin. Endocrinol. Metab.94(8), 2773–2780 (2009).
   PubMed Web of Science ®Google Scholar
• Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med.148(9), 680–684 (2008).
   PubMed Web of Science ®Google Scholar
• Briot K, Cortet B, Trémollières F et al. Male osteoporosis: diagnosis and fracture risk evaluation. Joint Bone Spine76(2), 129–133 (2009).
   PubMed Web of Science ®Google Scholar
• Yu EW, Blackwell T, Ensrud KE et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif. Tissue. Int.83(4), 251–259 (2008).
   PubMed Web of Science ®Google Scholar
• Lim LS, Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Ensrud KE. Osteoporotic Fractures in Men (MrOS) Study Group. Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch. Intern. Med.168(7), 735–740 (2008).
   PubMedGoogle Scholar
• Haney EM, Chan BK, Diem SJ et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch. Intern. Med.167(12), 1246–1251 (2007).
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Walczak TS, Blackwell TL, Ensrud ER, Barrett-Connor E, Orwoll ES. Osteoporotic Fractures in Men (MrOS) Study Research Group. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology71(10), 723–730 (2008).
   PubMed Web of Science ®Google Scholar
• Nabipour I, Sambrook PN, Blyth FM et al. Serum uric acid is associated with bone health in older men: a cross-sectional, population-based study. J. Bone Miner. Res.26(5), 955–964 (2011).
   PubMed Web of Science ®Google Scholar
• Fried LF, Shlipak MG, Stehman-Breen C et al. Kidney function predicts the rate of bone loss in older individuals: the Cardiovascular Health Study. J. Gerontol. A. Biol. Sci. Med. Sci.61(7), 743–748 (2006).
   PubMed Web of Science ®Google Scholar
• Jassal SK, von Muhlen D, Barrett-Connor E. Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study. J. Bone Miner. Res.22(2), 203–210 (2007).
   PubMed Web of Science ®Google Scholar
• Ishani A, Paudel M, Taylor BC et al. Renal function and rate of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Osteoporos. Int.19(11), 1549–1556 (2008).
   PubMed Web of Science ®Google Scholar
• Fried LF, Biggs ML, Shlipak MG et al. Association of kidney function with incident hip fracture in older adults. J. Am. Soc. Nephrol.18(1), 282–286 (2007).
   PubMed Web of Science ®Google Scholar
• Parsons JK, Mougey J, Lambert L et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int.104(1), 63–68 (2009).
   PubMed Web of Science ®Google Scholar
• Moayyeri A, Bingham SA, Luben RN, Wareham NJ, Khaw KT. Respiratory function as a marker of bone health and fracture risk in an older population. J. Bone Miner. Res.24(5), 956–963 (2009).
   PubMed Web of Science ®Google Scholar
• Dam TT, Harrison S, Fink HA, Ramsdell J, Barrett-Connor E; for the Osteoporotic Fractures in Men (MrOS) Research Group. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos. Int.21(8), 1341–1349 (2010).
   PubMed Web of Science ®Google Scholar
• Fink HA, Kuskowski MA, Orwoll ES, Cauley JA, Ensrud KE; Osteoporotic Fractures in Men (MrOS) Study Group. Association between Parkinson’s disease and low bone density and falls in older men: the osteoporotic fractures in men study. J. Am. Geriatr. Soc.53(9), 1559–1564 (2005).
   PubMed Web of Science ®Google Scholar
• Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Orwoll ES, Ensrud KE; Osteoporotic Fractures in Men (MrOS) Study Group. Association of Parkinson’s disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos. Int.19(9), 1277–1282 (2008).
   PubMed Web of Science ®Google Scholar
• Abou-Raya S, Helmii M, Abou-Raya A. Bone and mineral metabolism in older adults with Parkinson’s disease. Age Aging38(6), 675–680 (2009).
   PubMed Web of Science ®Google Scholar
• Pietschmann P, Kudlacek S, Grisar J et al. Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur. J. Clin. Invest.31(5), 444–451 (2001).
   PubMed Web of Science ®Google Scholar
• Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA. Bone resorption and osteoporotic fractures in elderly men: The Dubbo Osteoporosis Epidemiology Study. J. Bone Miner. Res.20(4), 579–587 (2005).
   PubMed Web of Science ®Google Scholar
• Scholtissen S, Guillemin F, Bruyère O et al. Assessment of determinants for osteoporosis in elderly men. Osteoporos. Int.20(7), 1157–1166 (2009).
   PubMed Web of Science ®Google Scholar
• Lormeau C, Soudan B, d’Herbomez M, Pigny P, Duquesnoy B, Cortet B. Sex hormone-binding globulin, estradiol, and bone turnover markers in male osteoporosis. Bone34(6), 933–939 (2004).
   PubMed Web of Science ®Google Scholar
• Phipps KR, Chan BK, Madden TE et al. Longitudinal study of bone density and periodontal disease in men. J. Dent. Res.86(11), 1110–1114 (2007).
   PubMed Web of Science ®Google Scholar
• Laudisio A, Marzetti E, Antonica L et al. Masticatory dysfunction is associated with osteoporosis in older men. J. Clin. Periodontol.34(11), 964–968 (2007).
   PubMed Web of Science ®Google Scholar
• Brennan SL, Henry MJ, Wluka AE, Nicholson GC, Kotowicz MA, Pasco JA. Socioeconomic status and bone mineral density in a population-based sample of men. Bone46(4), 993–999 (2010).
   PubMed Web of Science ®Google Scholar
• Nabipour I, Cumming R, Handelsman DJ et al. Socioeconomic status and bone health in community-dwelling older men: the CHAMP Study. Osteoporos. Int.22(5), 1343–1353 (2010).
   PubMed Web of Science ®Google Scholar
• Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann. Intern. Med.114(11), 919–923 (1991).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Nevitt MC, Browner WS et al. Study of Osteoporotic Fractures Research Group. Risk factors for hip fracture in white women. N. Engl. J. Med.332(12), 767–773 (1995).
   PubMed Web of Science ®Google Scholar
• Ismail AA, Cooper C, Felsenberg D et al. European Vertebral Osteoporosis Study Group. Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. Osteoporos. Int.9(3), 206–213 (1999).
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Center JR, Sambrook PN, Eisman JA. Risk factors for proximal humerus, forearm, and wrist fractures in elderly men and women: the Dubbo Osteoporosis Epidemiology Study. Am. J. Epidemiol.153(6), 587–595 (2001).
   PubMed Web of Science ®Google Scholar
• National Arthritis and Musculoskeletal Conditions Advisory Group (NAMSCAG). Evidence to support the national action plan for osteoarthritis, rheumatoid arthritis and osteoporosis: opportunities to improve health-related quality of life and reduce the burden of disease and disability. Australian Government Department of Health and Aging, Canberra, Australia (2004).
   Google Scholar
• Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ. Tech. Rep. Ser.843, 1–129 (1994).
   PubMed Web of Science ®Google Scholar
• Pfeilschifter J. German Specialist Organisation for Osteology. 2006 DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines. Exp. Clin. Endocrinol. Diabetes114(10), 611–622 (2006).
   PubMed Web of Science ®Google Scholar
• Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can. Med. Assoc. J.167(10 Suppl.), S1–S34 (2002).
   PubMed Web of Science ®Google Scholar
• Eisman JA, Ebeling PR, Ewald D et al. Clinical guideline for the treatment of osteoporosis in postmenopausal women and older men. The Royal Australian College of General Practitioners (RACGP). Melbourne, Australia (2010).
   Google Scholar
• Marín F, González-Macías J, Díez-Pérez A, Palma S, Delgado-Rodríguez M. Relationship between bone quantitative ultrasound and fractures: a meta-analysis. J. Bone Miner. Res.21(7), 1126–1135 (2006).
   PubMed Web of Science ®Google Scholar
• Guglielmi G, Lang TF. Quantitative computed tomography. Semin. Musculoskelet. Radiol.6(3), 219–227 (2002).
   PubMedGoogle Scholar
• Glüer CC, Engelke K, Lang TF, Grampp S, Genant HK. Quantitative computed tomography (QCT) of the lumbar spine and appendicular skeleton. Eur. J. Radiol.20(3), 173–178 (1995).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Nevitt MC et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet341(8837), 72–75 (1993).
   PubMed Web of Science ®Google Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ312(7041), 1254–1259 (1996).
   PubMed Web of Science ®Google Scholar
• Torgerson DJ, Campbell MK, Thomas RE, Reid DM. Prediction of perimenopausal fractures by bone mineral density and other risk factors. J. Bone Miner. Res.11(2), 293–297 (1996).
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Bauer DC, Vogt TM, Fox KM. Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med.124(2), 187–196 (1996).
   PubMed Web of Science ®Google Scholar
• Leslie WD, Lix LM, Tsang JF et al. Single-site vs multisite bone density measurement for fracture prediction. Arch. Intern. Med.167(15), 1641–1647 (2007).
   PubMedGoogle Scholar
• Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos. Int.3(3), 120–126 (1993).
   PubMed Web of Science ®Google Scholar
• The European Prospective Osteoporosis Study (EPOS) Group. The relationship between bone density and incident vertebral fracture in men and women. J. Bone Miner. Res.17(12), 2214–2221 (2002).
   PubMed Web of Science ®Google Scholar
• de Laet CE, van der Klift M, Hofman A, Pols HA. Osteoporosis in men and women: a story about bone mineral density thresholds and hip fracture risk. J. Bone Miner. Res.17(12), 2231–2236 (2002).
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis J, Gullberg G. Mortality, morbidity, and assessment of fracture risk in male osteoporosis. Calcif. Tissue Int.69(4), 182–184 (2001).
   PubMed Web of Science ®Google Scholar
• Maggio D, McCloskey EV, Camilli L et al. Short-term reproducibility of proximal femur bone mineral density in the elderly. Calcif. Tissue Int.63(4), 296–299 (1998).
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int.19(4), 385–397 (2008).
   PubMed Web of Science ®Google Scholar
• Nguyen ND, Frost SA, Center JR et al. Development of a nomogram for individualising hip fracture risk in men and women. Osteoporos. Int.18(8), 1109–1117 (2007).
   PubMed Web of Science ®Google Scholar
• Nguyen ND, Frost SA, Center JR et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos. Int.19(10), 1431–1444 (2008).
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Nguyen ND, Center JR, Pocock NA, Eisman JA, Nguyen TV. Prognosis of fracture: evaluation of predictive accuracy of the FRAX algorithm and Garvan nomogram. Osteoporos. Int.21(5), 863–871 (2010).
   PubMed Web of Science ®Google Scholar
• Waddell G, Somerville D, Henderson I, Newton M. Objective clinical evaluation of physical impairment in chronic low back pain. Spine17(6), 617–628 (1992).
   PubMed Web of Science ®Google Scholar
• Kaptoge S, Armbrecht G, Felsenberg D et al. Whom to treat? The contribution of vertebral X-rays to risk-based algorithms for fracture prediction: results from the European Prospective Osteoporosis Study. Osteoporos. Int.17(9), 1369–1381 (2006).
   PubMed Web of Science ®Google Scholar
• Delmas PD, van de Langerijt L, Watts NB et al. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J. Bone Miner. Res.20(4), 557–563 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrar L, Jiang G, Cawthon PM et al. Identification of vertebral fracture and non-osteoporotic short vertebral height in men: the MrOS study. J. Bone Miner. Res.22(9), 1434–1441 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrar L, Eastell R. Identification of vertebral deformities in men: comparison of morphometric radiography and morphometric X-ray absorptiometry. Osteoporos. Int.10(2), 167–174 (1999).
   PubMed Web of Science ®Google Scholar
• Pye SR, Tobias J, Silman AJ, Reeve J, O’Neill TW; EPOS Study Group. Childhood fractures do not predict future fractures: results from the European Prospective Osteoporosis Study. J. Bone Miner. Res.24(7), 1314–1318 (2009).
   PubMed Web of Science ®Google Scholar
• Gärdsell P, Johnell O, Nilsson BE, Nilsson JA. The predictive value of fracture, disease, and falling tendency for fragility fractures in women. Calcif. Tissue Int.45(6), 327–330 (1989).
   PubMed Web of Science ®Google Scholar
• Lauritzen JB, Schwarz P, McNair P, Lund B, Transbøl I. Radial and humeral fractures as predictors of subsequent hip, radial or humeral fractures in women, and their seasonal variation. Osteoporos. Int.3(3), 133–137 (1993).
   PubMed Web of Science ®Google Scholar
• Karlsson MK, Hasserius R, Obrant KJ. Individuals who sustain nonosteoporotic fractures continue to also sustain fragility fractures. Calcif. Tissue Int.53(4), 229–231 (1993).
   PubMed Web of Science ®Google Scholar
• Johansson C, Mellstrom D. An earlier fracture as a risk factor for new fracture and its association with smoking and menopausal age in women. Maturitas24(1–2), 97–106 (1996).
   PubMed Web of Science ®Google Scholar
• Honkanen R, Tuppurainen M, Kroger H, Alhava E, Puntila E. Associations of early premenopausal fractures with subsequent fractures vary by sites and mechanisms of fractures. Calcif. Tissue Int.60(4), 327–331 (1997).
   PubMed Web of Science ®Google Scholar
• Mackey D, Lui L, Cawthon P et al. High-trauma fractures and low bone mineral density in older women and men. JAMA298(20), 2381–2388 (2007).
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Hamann C, Ebeling PR. Approach to the patient with secondary osteoporosis. Eur. J. Endocrinol.162(6), 1009–1020 (2010).
   PubMed Web of Science ®Google Scholar
• Kraenzlin ME, Anliker M, Griesmacher A. Laboratory assessment of osteoporosis. Ther. Umsch.65(9), 513–518 (2008).
   PubMedGoogle Scholar
• Kelman A, Lane NE. The management of secondary osteoporosis. Best. Pract. Res. Clin. Rheumatol.19(6), 1021–1037 (2005).
   PubMed Web of Science ®Google Scholar
• Holick MF. The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol. Aspects Med.29(6), 361–368 (2008).
   PubMed Web of Science ®Google Scholar
• Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am. J. Clin. Nutr.87(4), 1080S–1086S (2008).
   PubMed Web of Science ®Google Scholar
• Yetley EA. Assessing the vitamin D status of the US population. Am. J. Clin. Nutr.88(2), 558S–564S (2008).
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B. Serum 25-hydroxyvitamin D and functional outcomes in the elderly. Am. J. Clin. Nutr.88(2), 537S–540S (2008).
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D deficiency. N. Engl. J. Med. 19; 357(3), 266–281 (2007).
   PubMed Web of Science ®Google Scholar
• Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging24(12), 1017–1029 (2007).
   PubMed Web of Science ®Google Scholar
• Holick MF. Sunlight, UV-radiation, vitamin D and skin cancer: how much sunlight do we need? Adv. Exp. Med. Biol.624, 1–15 (2008).
   PubMed Web of Science ®Google Scholar
• Prentice A, Goldberg GR, Schoenmakers I. Vitamin D across the lifecycle: physiology and biomarkers. Am. J. Clin. Nutr.88(2), 500S–506S (2008).
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Staehelin HB. Importance of vitamin D and calcium at older age. Int. J. Vitam. Nutr. Res.78(6), 286–292 (2008).
   PubMed Web of Science ®Google Scholar
• Isenor JE, Ensom MH. Is there a role for therapeutic drug monitoring of vitamin D level as a surrogate marker for fracture risk? Pharmacotherapy30(3), 254–264 (2010).
   PubMed Web of Science ®Google Scholar
• van Daele PL, Seibel MJ, Burger H et al. Case control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. BMJ312(7029), 482–483 (1996).
   PubMed Web of Science ®Google Scholar
• Garnero P, Hausherr E, Chapuy MC et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J. Bone Miner. Res.11(10), 1531–1538 (1996).
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med.361(8), 756–765 (2009).
   PubMed Web of Science ®Google Scholar
• Eastell R, Chen P, Saag KG et al. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone46(4), 929–934 (2010).
   PubMed Web of Science ®Google Scholar
• Ryder KM, Tanner SB, Carbone L et al. Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis. J. Bone Miner. Metab.28(2), 233–239 (2010).
   PubMed Web of Science ®Google Scholar
• Glover SJ, Eastell R, McCloskey EV et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone45(6), 1053–1058 (2009).
   PubMed Web of Science ®Google Scholar
• Ebeling PR. Clinical practice. Osteoporosis in men. N. Engl. J. Med.358(14), 1474–1482 (2008).
   PubMed Web of Science ®Google Scholar
• Bolland MJ, Avenell A, Baron JA et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ341, c3691 (2010).
   PubMed Web of Science ®Google Scholar
• Lewis JR, Calver J, Zhu K, Flicker L, Prince RL. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J. Bone Miner. Res.26(1), 35–41 (2010).
   Web of Science ®Google Scholar
• Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta analysis. Lancet370(9588), 657–666 (2007).
   PubMed Web of Science ®Google Scholar
• Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am. J. Clin. Nutr.73(2), 288–294 (2001).
   PubMed Web of Science ®Google Scholar
• Ebeling PR, Wark JD, Yeung S et al. Effects of calcium or calcitriol on bone mineral density, bone turnover and fractures in men with primary osteoporosis. J. Clin. Endocrinol. Metab.86(9), 4098–4103 (2001).
   PubMed Web of Science ®Google Scholar
• Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med.343(9), 604–610 (2000).
   PubMed Web of Science ®Google Scholar
• Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol. Int.26(5), 427–431 (2006).
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Orwoll E, Goemaere S et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos. Int.16(5), 510–516 (2005).
   PubMed Web of Science ®Google Scholar
• Sato Y, Iwamoto J, Kanoko T et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch. Intern. Med.165(15), 1743–1748 (2005).
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colón-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med.357(18), 1799–1809 (2007).
   PubMed Web of Science ®Google Scholar
• Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab.82(8), 2386–2390 (1997).
   PubMed Web of Science ®Google Scholar
• Leifke E, Körner HC, Link TM, Behre HM, Peters PE, Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur. J. Endocrinol.138(1), 51–58 (1998).
   PubMed Web of Science ®Google Scholar
• Aminorroaya A, Kelleher S, Conway AJ, Ly LP, Handelsman DJ. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur. J. Endocrinol.152(6), 881–886 (2005).
   PubMed Web of Science ®Google Scholar
• Araujo AB, O‘Donnell AB, Brambilla DJ et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab.89(12), 5920–5926 (2004).
   PubMed Web of Science ®Google Scholar
• Finklestein JS, Klibanski A, Neer RM et al. Increases in bone density during treatment of men with idiopathic hypogonadotrophic hypogonadism. J. Clin. Endocrinol. Metab69(4), 776–783 (1989).
   PubMed Web of Science ®Google Scholar
• Amory JK, Watts NB, Easley KA et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab.89(2), 503–510 (2004).
   PubMed Web of Science ®Google Scholar
• Benito M, Vasilic B, Wehrli FW et al. Effects of testosterone replacement on trabecular architecture in hypogonadal men. J. Bone Miner. Res.20(10), 1785–1791 (2005).
   PubMed Web of Science ®Google Scholar
• Page ST, Amory JK, Bowman FD et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J. Clin. Endocrinol. Metab.90(3), 1502–1510 (2005).
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab.84(6), 1966–1972 (1999).
   PubMed Web of Science ®Google Scholar
• Anderson F, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis – effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone18(2), 171–177 (1996).
   PubMed Web of Science ®Google Scholar
• Anderson F, Francis RM, Peaston RT, Wastell HJ. Androgen supplementation in eugonadal men with osteoporosis: effects of six months’ treatment on markers of bone formation and resorption. J. Bone Miner. Res.12(3), 472–478 (1997).
   PubMed Web of Science ®Google Scholar
• Ebeling PR. Androgens and osteoporosis. Curr. Opin. Endocrinol. Diabetes Obes.17(3), 284–292 (2010).
   PubMedGoogle Scholar
• Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res.18(1), 9–17 (2003).
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hernández Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med.361(8), 745–755 (2009).
   PubMed Web of Science ®Google Scholar
• Smith MR, Morton RA, Barnette KG et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J. Urol.184(4), 1316–1321 (2010).
   PubMed Web of Science ®Google Scholar
• Grant AM, Avenell A, Campbell MK et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet365(9471), 1621–1628 (2005).
   PubMed Web of Science ®Google Scholar
• Milgrom C, Finestone A, Novack V et al. The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. Bone35(2), 418–424 (2004).
   PubMed Web of Science ®Google Scholar
• Kanaji A, Higashi M, Namisato M et al. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. Lepr. Rev.77(2), 147–153 (2006).
   PubMed Web of Science ®Google Scholar
• Trovas GP, Lyritis GP, Galanos A et al. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J. Bone Miner. Res.17(3), 521–527 (2002).
   PubMed Web of Science ®Google Scholar
• Toth E, Csupor E, Meszaros S et al. The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures – an open label study. Bone36(1), 47–51 (2005).
   PubMed Web of Science ®Google Scholar
• Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif. Tissue Int.69(4), 242–247 (2001).
   PubMed Web of Science ®Google Scholar
• Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD. Once weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J. Bone Miner. Res.24(4), 719–725 (2009).
   PubMed Web of Science ®Google Scholar
• Campbell IA, Douglas JG, Francis RM et al. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax59(9), 761–768 (2004).
   PubMed Web of Science ®Google Scholar
• Eriksen EF, Lyles KW, Colón-Emeric CS et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J. Bone Miner. Res.24(7), 1308–1313 (2009).
   PubMed Web of Science ®Google Scholar
• Colón-Emeric CS, Mesenbrink P, Lyles KW et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J. Bone Miner. Res.25(1), 91–97 (2010).
   PubMed Web of Science ®Google Scholar
• Orwoll E, Miller PD, Adachi JD et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J. Bone Miner. Res.25(10), 2239–2250 (2010).
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Bilezikian JP. Clinical review 123: anabolic therapy for osteoporosis. J. Clin. Endocrinol. Metab.86(3), 957–964 (2001).
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med.349(13), 1216–1226 (2003).
   PubMed Web of Science ®Google Scholar
• Miller PD, Delmas PD, Lindsay R et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab.93(10), 3785–3793 (2008).
   PubMed Web of Science ®Google Scholar
• Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide[human parathyroid hormone (1–34)]. Osteoporos. Int.15(12), 992–997 (2004).
   PubMed Web of Science ®Google Scholar